Oral MTX-531 for advanced solid tumors
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests an experimental oral drug called MTX-531 in people with certain advanced cancers that have not responded to standard treatments. The study aims to see if the drug shrinks tumors or slows their growth, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these cancers that is advanced or has spread: endometrial cancer, HER2-negative breast cancer, head and neck squamous cell carcinoma, colorectal cancer with normal RAS and BRAF genes, or another solid tumor with a PIK3CA mutation.
- You must have already tried certain treatments for your cancer, depending on the type (for example, immunotherapy, platinum chemotherapy, hormone therapy, or CDK4/6 inhibitors).
- You must be able to swallow pills and have a working digestive system.
- You must be in reasonably good general health, with adequate organ function and blood counts.
- You must not be pregnant or breastfeeding and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Hear when a new Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.